Fig. 2From: In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutantsBacktracking nilotinib-resistant mutations by DS. See legend to Fig. 1 for explanations and abbreviationsBack to article page